Literature DB >> 11994436

Human B cells become highly responsive to macrophage-inflammatory protein-3 alpha/CC chemokine ligand-20 after cellular activation without changes in CCR6 expression or ligand binding.

Fang Liao1, Aiko-Konno Shirakawa, John F Foley, Ronald L Rabin, Joshua M Farber.   

Abstract

CCR6 is the only known receptor for the chemokine macrophage-inflammatory protein (MIP)-3alpha/CC chemokine ligand (CCL)20. We have shown previously that CCR6 is expressed on peripheral blood B cells, but CCR6 activity on these cells is low in in vitro assays. We report that MIP-3alpha/CCL20-induced calcium flux and chemotaxis can be enhanced significantly on peripheral blood and tonsillar B cells after activation by cross-linking surface Ag receptors. Of particular interest is the fact that the enhanced activity on B cells was not associated with an increase in CCR6 expression as assessed by levels of receptor mRNA, surface staining, or MIP-3alpha/CCL20 binding sites, or by a change in the affinity of the receptor for ligand. These data convincingly demonstrate that responses to a chemokine can be regulated solely by changes in the downstream pathways for signal transduction resulting from Ag receptor activation, and establish CCR6 as an efficacious receptor on human B cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994436     DOI: 10.4049/jimmunol.168.10.4871

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

Review 1.  Chemokine receptors and leukocyte trafficking in the mucosal immune system.

Authors:  Ifor R Williams
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Selectivity in the Use of Gi/o Proteins Is Determined by the DRF Motif in CXCR6 and Is Cell-Type Specific.

Authors:  Satya P Singh; John F Foley; Hongwei H Zhang; Darrell E Hurt; Jennifer L Richards; Craig S Smith; Fang Liao; Joshua M Farber
Journal:  Mol Pharmacol       Date:  2015-08-27       Impact factor: 4.436

Review 3.  B Cell Activation and Response Regulation During Viral Infections.

Authors:  Jonathan H Lam; Fauna L Smith; Nicole Baumgarth
Journal:  Viral Immunol       Date:  2020-04-23       Impact factor: 2.257

Review 4.  Chemokine control of lymphocyte trafficking: a general overview.

Authors:  Jens V Stein; César Nombela-Arrieta
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

5.  Effects of MIP-1 alpha, MIP-3 alpha, and MIP-3 beta on the induction of HIV Gag-specific immune response with DNA vaccines.

Authors:  Ruijiang Song; Shuqin Liu; Kam W Leong
Journal:  Mol Ther       Date:  2007-03-13       Impact factor: 11.454

6.  Pathway-selective suppression of chemokine receptor signaling in B cells by LPS through downregulation of PLC-β2.

Authors:  Aiko-Konno Shirakawa; Fang Liao; Hongwei H Zhang; Michael N Hedrick; Satya P Singh; Dianqing Wu; Joshua M Farber
Journal:  Cell Mol Immunol       Date:  2010-09-27       Impact factor: 11.530

7.  CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia.

Authors:  Mercedes Borge; Paula Romina Nannini; Jeremías Gastón Galletti; Pablo Elías Morande; Julio Sánchez Avalos; Raimundo Fernando Bezares; Mirta Giordano; Romina Gamberale
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

Review 8.  CCR6 as a possible therapeutic target in psoriasis.

Authors:  Michael N Hedrick; Anke S Lonsdorf; Sam T Hwang; Joshua M Farber
Journal:  Expert Opin Ther Targets       Date:  2010-09       Impact factor: 6.902

9.  Activation and function of the mTORC1 pathway in mast cells.

Authors:  Mi-Sun Kim; Hye Sun Kuehn; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

10.  CX3CR1 is expressed by human B lymphocytes and mediates [corrected] CX3CL1 driven chemotaxis of tonsil centrocytes.

Authors:  Anna Corcione; Elisa Ferretti; Maria Bertolotto; Franco Fais; Lizzia Raffaghello; Andrea Gregorio; Claudya Tenca; Luciano Ottonello; Claudio Gambini; Glaucia Furtado; Sergio Lira; Vito Pistoia
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.